Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016

Date: November 9, 2016
Pages: 267
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RA1B2886D56EN
Leaflet:

Download PDF Leaflet

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H2 2016, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.

Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 11, 50 and 14 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 4, 13 and 4 molecules, respectively.Respiratory Syncytial Virus (RSV) Infections.

Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Respiratory Syncytial Virus (RSV) Infections Overview
Therapeutics Development
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies
Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes
Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance
Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies
Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes
Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development
Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment
Drug Profiles
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products
Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2016
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abivax SA, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aviragen Therapeutics, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Curevac AG, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies S.A., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gene Techno Science Co., Ltd., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Globavir Biosciences, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ILiAD Biotechnologies, LLC, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ilyang Pharmaceutical Co., Ltd, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine Inc, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by mAbxience S.A., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune LLC, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co., Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis B.V., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mymetics Corporation, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corporation, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by NeuClone Pty Ltd, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Profectus BioSciences, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spider Biotech, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Themis Bioscience GmbH, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Trellis Bioscience, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vault Pharma Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart Inc, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VaxInnate Corporation, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VBI Vaccines Inc, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Visterra, Inc., H2 2016
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VLP Biotech, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2016
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..1), H2 2016
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..2), H2 2016
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..3), H2 2016
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..4), H2 2016
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2016
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


West Nile Virus Infections - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 71 pages

Ask Your Question

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: